Lumenis (LMNS) Earns Daily Media Impact Score of 0.12

News coverage about Lumenis (NASDAQ:LMNS) has trended somewhat positive recently, according to AlphaOne. The research group, a subsidiary of Accern, identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lumenis earned a media sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also gave media coverage about the medical equipment provider an impact score of 57 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the company’s share price in the next several days.

Shares of Lumenis (NASDAQ:LMNS) remained flat at $13.76 during midday trading on Friday. Lumenis has a 52 week low of $8.45 and a 52 week high of $13.97. The stock has a 50 day moving average price of $13.80 and a 200 day moving average price of $12.89.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/05/19/lumenis-lmns-earns-daily-media-impact-score-of-0-12.html.

About Lumenis

Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.

5 Day Chart for NASDAQ:LMNS

Receive News & Ratings for Lumenis Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply